McKesson extends CVS Health distribution deal to 2032
The distributor also reaffirmed its fiscal 2027 adjusted EPS guidance of $44.20 to $45.00.
McKesson announced on October 1, 2026, that it has signed an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032. The arrangement covers deliveries to mail order, specialty pharmacies, retail locations, and distribution centers.
Brian Tyler, chair and chief executive officer of McKesson, highlighted that the two companies have worked together for more than 25 years. The agreement remains subject to the execution of a final definitive contract.
Alongside the deal, McKesson reaffirmed its fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00. The company also maintained its long-term adjusted EPS growth rate target of 13% to 16%. McKesson plans to provide further updates during its second-quarter earnings call on November 4, 2026.
Share prices can rise and fall. Past performance does not guarantee future results. This article is news, not investment advice.
Newsletter
Markets in your inbox, weekly
Latin America-focused analysis, investment themes and the week in finance.